Recombinant Human Fms-Related Tyrosine Kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), His-tagged

• Cat.No.: FLT1-1222H
• Product Overview: Recombinant humanFLT1 containing amino acids 783-end and an N-terminal His tag.

Specification

• Cat. No.: FLT1-1222H
• Description: FLT1is a protein that in humans is encoded by the FLT1 gene. FLT1 belongs to thesrc gene family and is related to oncogene ROS. Like other members of thisfamily, it shows tyrosine protein kinase activity that is important for thecontrol of cell proliferation and differentiation.
• Source: Baculovirus infectedSf9 cells
• Species: Human
• Form: Liquid in25 mM Tris-HCl, pH 8.0 + 100 mM NaCl + 0.05% Tween-20 + 50% glycerol + 3 mMDTT.
• Molecular Weight: 67.5 kDa
• Specific Activity: 170 U/mg. One unitis defined as the amount of enzyme that will transfer 1 nmol phosphate to thetyrosine substrate per minute at pH 7.4 and 30°C. Assay buffer: 50 mM HEPES,pH 7.4 + 3 mM MgCl2 + 3 mM MnCl2 + 1 mM DTT + 3 µM Na-orthovanadate + 0.1 mMATP + 30 µg/ml Poly (Glu:Tyr)4:1 substrate + 2 µg /ml recombinant FLT1.
• Storage: Stable for 6 monthsin working aliquots at -80°C. Avoid repeated freeze-thaw cycles.
• Protein length: 783-end

Gene Information

• Gene Name: FLT1 fms-related tyrosine kinase 1(vascular endothelial growth factor/vascular permeability factor receptor) [ Homosapiens ]
• Official Symbol: FLT1
• Synonyms: FLT1; fms-related tyrosinekinase 1 (vascular endothelial growth factor/vascular permeability factorreceptor); FLT; VEGFR1; FRT; vascular endothelial growth factor receptor 1;EC 2.7.10.1; VEGFR-1; Vascular permeability factor receptor; Flt-1;Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase FRT; Fms-liketyrosine kinase 1
• Gene ID: 2321
• mRNA Refseq: NM_001159920
• Protein Refseq: NP_001153392
• MIM: 165070
• UniProt ID: P17948
• Chromosome Location: 13q12
• Pathway: Cytokine-cytokinereceptor interaction; Endocytosis; Focal Adhesion; Glypican 1 network;HIF-2-alpha transcription factor network; Id Signaling Pathway; Neurophilininteractions with VEGF and VEGFR; Rheumatoid arthritis; S1P3 pathway; SignalTransduction; Signaling by VEGF; Signaling events mediated by VEGFR1 andVEGFR2; VEGF binds to VEGFR leading to receptor dimerization; VEGFligand-receptor interactions; VEGFR1 specific signals
• Function: ATP binding; growth factorbinding; identical protein binding; nucleotide binding; receptor activity;transferase activity; vascular endothelial growth factor receptor activity

Reviews

07/08/2019

the FLT1 protein is an excellent choice for researchers due to its high quality, reliability, and the comprehensive technical support provided by the manufacturer.

07/17/2018

The manufacturer of FLT1 protein provides excellent technical support, ensuring that researchers receive prompt assistance and guidance when encountering any challenges or difficulties.

05/27/2016

Researchers can confidently incorporate FLT1 protein into their experiments, knowing that they have access to a reliable resource that will meet their experimental needs effectively.

Q&As

How is FLT1 linked to preeclampsia in pregnancy?

Elevated levels of soluble FLT1 have been associated with preeclampsia, a pregnancy complication. Soluble FLT1 acts as a decoy receptor, reducing the bioavailability of VEGF and contributing to vascular dysfunction.

How does FLT1 contribute to retinal diseases such as diabetic retinopathy?

FLT1 has been implicated in retinal diseases like diabetic retinopathy, where abnormal blood vessel growth can lead to vision impairment. Inhibiting FLT1 may help regulate angiogenesis in such conditions.

How is FLT1 expression regulated in the human body?

FLT1 expression is regulated by various factors, including VEGF itself, as well as hypoxia and inflammation. These factors influence the balance of angiogenic signaling.

Can FLT1 be a biomarker for certain diseases?

Yes, elevated levels of soluble FLT1 have been investigated as potential biomarkers for conditions like preeclampsia, cancer, and certain cardiovascular diseases.

Can FLT1 be targeted for anti-angiogenic therapy?

Yes, targeting FLT1 is a strategy for anti-angiogenic therapy. Inhibiting FLT1 can impede blood vessel formation, limiting the blood supply to tumors and potentially slowing their growth.